In late September, DyDo Pharma, our sub-licensee in Japan, secured regulatory approval for FIRDAPSE 10-milligram tablets for ...

Oppenheimer analyst Leland Gershell maintained a Buy rating on Catalyst Pharma (CPRX – Research Report) today and set a price target of ...

Andrew Fein, an analyst from H.C. Wainwright, reiterated the Buy rating on Catalyst Pharma (CPRX – Research Report). The associated price ...